Industry Newsbiopharmahypersomnolenceneurologyacquisition
Alkermes Projects Transformational 2025 With Acquisition Plans
5.0
Alkermes plc reports bullish analyst coverage and strategic moves as executives call 2025 transformational. At the Evercore conference on Dec. 3 CEO Richard Pops highlighted positive NT1 and NT2 data and plans to acquire Avadel (≈$275 million topline) to support the planned oral alixorexton launch. As of Dec. 19 the median one-year analyst price target is $46.17, implying roughly 62.3% upside.
Key Points
- 1Reports show 11 of 15 analysts rate Alkermes Buy; median target $46.17 (62.3% upside).
- 2CEO Richard Pops calls 2025 transformational, citing positive NT1/NT2 data and hypersomnolence focus.
- 3Plans to acquire Avadel (~$275M revenue) aim to support alixorexton oral launch for sleep disorders.
Scoring Rationale
Moderate novelty and credible executive and analyst confirmations, but company-specific focus limits broader industry and data-science relevance.
Sources
Public references used for this report.
Practice with real Health & Insurance data
90 SQL & Python problems · 15 industry datasets
Used by DS/ML engineers at top companies
250 free problems · No credit card
See all Health & Insurance problems
